A Prospective Non-interventional Study Documenting the Management and Outcomes of Adult Patients With Acute Myeloid Leukemia (AML)
Latest Information Update: 05 Feb 2024
At a glance
- Drugs Cytarabine/daunorubicin (Primary) ; Gemtuzumab ozogamicin (Primary) ; Anthracyclines; Azacitidine; Cytarabine; Midostaurin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms ALFAPPP
- 30 Jan 2024 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2032.
- 16 Feb 2023 Status changed from not yet recruiting to recruiting.
- 21 Jul 2021 Planned initiation date changed from 1 Apr 2021 to 15 Sep 2021.